drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A humanized IgG1 monoclonal antibody given subcutaneously that binds c-Kit (CD117) and blocks stem cell factor (SCF) signaling, leading to inhibition/depletion of c-Kit–positive cells, particularly airway mast cells, to reduce early and late allergic bronchoconstriction and airway hyperresponsiveness; may also impact c-Kit+ hematopoietic progenitors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal, Humanized
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting c‑Kit (CD117) that blocks stem cell factor (SCF) signaling, leading to functional inhibition and depletion of c‑Kit–positive cells—particularly airway mast cells—thereby reducing allergic activation/bronchoconstriction and airway hyperresponsiveness; may also affect c‑Kit+ hematopoietic progenitors.
drug_name
Briquilimab (JSP191)
nct_id_drug_ref
NCT06592768